Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 4/20 | 0.62 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.62 |
| ▸ | ABL1 | P00519 | 5/20 | 0.56 |
| ▸ | AXL | P30530 | 2/20 | 0.56 |
| ▸ | SRC | P12931 | 3/20 | 0.53 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.47 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.47 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.46 |
| ▸ | PLK4 | O00444 | 1/20 | 0.46 |
| ▸ | ACOX3 | O15254 | 1/20 | 0.46 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.46 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 1/20 | 0.46 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.46 |
| ▸ | STK10 | O94804 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2024393 | 0.85 | ABL1 (0.53) | GRNSORT1ABL1AXLSRC | |
| SCHEMBL1521770 | 0.81 | ABL1 (0.53) | ABL1AXLSRCPTK2PTK2B | |
| SCHEMBL2083392 | 0.81 | GRN (0.59) | GRNSORT1ABL1AXLSRC | |
| SCHEMBL30904919 | 0.80 | ABL1 (0.52) | ABL1AXLSRCPTK2PTK2B | |
| SCHEMBL29186401 | 0.80 | ABL1 (0.52) | ABL1AXLSRCPTK2PTK2B | |
| SCHEMBL2025827 | 0.80 | GRN (0.57) | GRNSORT1ABL1AXLSRC | |
| SCHEMBL28708290 | 0.80 | ABL1 (0.55) | GRNSORT1ABL1AXLSRC | |
| SCHEMBL2028916 | 0.79 | ALDH1A1 (0.62) | ABL1AXLSRCPTK2PTK2B | |
| SCHEMBL2083920 | 0.79 | ABL1 (0.80) | ABL1AXLSRCPTK2PTK2B | |
| SCHEMBL28700821 | 0.78 | ABL1 (0.67) | ABL1AXLSRCPTK2PTK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2073811-B1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS LLC (US) | 2015-03-11 | — | — | EP | disclosed |
| US-8586565-B2 | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| WO-2013036232-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-03-14 | — | — | WO | disclosed |
| US-20120225057-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-09-06 | — | — | US | disclosed |
| US-20110136760-A1 | Kinase Inhibitors Useful for the Treatment of Myleoproliferative Diseases and other Proliferative Diseases | DECIPHERA PHARMACEUTICALS, LLC | 2011-06-09 | — | — | US | disclosed |
| US-7790756-B2 | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2073811-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008046003-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-04-17 | — | — | WO | disclosed |
| US-20080090856-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225057-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | ABL1, MCL1, ABL2 | GRN 1743/4885SORT1 3912/4885ABL1 1/4885 |
| US-20080090856-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | MYLK3, MYLK, CDK3 | GRN 3478/4885SORT1 4656/4885ABL1 81/4885 |
| US-20110136760-A1 | Kinase Inhibitors Useful for the Treatment of Myleoproliferative Diseases and other Proliferative Diseases | MYLK3, MYLK, CDK3 | GRN 3478/4885SORT1 4656/4885ABL1 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.